Table 1.
Characteristics of the study participants by vaccination status
| Unvaccinated, N(%) | Partly vaccinated, N(%) | Fully vaccinated, N(%) | |
|---|---|---|---|
| Total | 60 | 23 | 38 |
| Gender | |||
| Female | 31 (51.6%) | 5 (21.7%) | 10 (26.3%) |
| Male | 29 (48.3%) | 18 (78.2%) | 28 (73.6%) |
| Age | |||
| 0–11 | 14 (23.3%) | NA | NA |
| 12–17 | 4 (6.6%) | 2 (8.6%) | 0 (0%) |
| 18–29 | 16 (26.6%) | 10 (43.4%) | 15 (39.4%) |
| 30–49 | 15 (25.0%) | 6 (26.0%) | 16 (42.1%) |
| 50–74 | 9 (15.0%) | 4 (17.3%) | 6 (15.7%) |
| 75 + | 2 (3.3%) | 0 (0%) | 1 (2.6%) |
| Vaccine received | |||
| Sinovac | NA | 14 (60.8%) | 10 (26.3%) |
| Sinopharm | NA | 7 (30.4%) | 18 (47.3%) |
| Pak‐vac | NA | 0 (0%) | 1 (2.6%) |
| Cansino | NA | 0 (0%) | 6 (15.7%) |
| Pfizer | NA | 0 (0%) | 2 (5.2%) |
| Moderna | NA | 1 (4.3%) | 0 (0%) |
| Astrazanca | NA | 1 (4.3%) | 1 (2.6%) |